Adenovirus-mediated E2F-1 gene transfer inhibits MDM2 expression and efficiently induces apoptosis in MDM2-overexpressing tumor cells

Clinical Cancer Research

Volumn 5, Issue 8, 1999, Pages 2242-2250

  Yang, Hai Liang ^a   Dong, Yan Bin ^a   Elliott, Mary Jane ^a   Liu, Ta Jen ^b   Atienza Jr , Cesar ^a   Stilwell, Ariel ^a   McMasters, Kelly M ^a,c  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; TRANSCRIPTION FACTOR E2F;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE S PHASE; GENE INACTIVATION; GENE TARGETING; IMMUNOBLOTTING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CARRIER PROTEINS; CASPASE 3; CASPASES; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE; CELL SURVIVAL; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; HUMANS; MICE; NEOPLASMS, EXPERIMENTAL; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; TRANSCRIPTION FACTOR DP1; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0242484074     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Landers, J. E., Cassel, S. L., and George, D. L. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res., 57: 3562-3568, 1997.
2. Leach, F. S., Tokino, T., Meltzer, P., Burrell, M., Oliner, J. D., Smith, S., Hill, D. E., Sidransky, D., Kinzler, K. W., and Vogelstein, B. p53 Mutation, and MDM2 amplification in human soft tissue sarcomas. Cancer Res., 53: 2231-2234, 1993.
3. Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., and Vogelstein, B. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature (Lond.), 362: 857-860, 1993.
4. Cordon-Cardo, C., Latres, E., Drobnjak, M., Oliva, M. R., Pollack, D., Woodruff, J. M., Marechal, V., Chen, J., Brennan, M. F., and Levine, A. J. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res., 54: 794-799, 1994.
5. Ladanyi, M., Cha, C., Lewis, R., Jhanwar, S. C., Huvos, A. G., and Healey, J. H. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res., 53: 16-18, 1993.
6. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69: 1237-1245, 1992.
7. Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., and Vogelstein, B. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature (Lond.), 362: 857-860, 1993.
8. Chen, J., Marechal, V., and Levine, A. J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol., 13: 4107-4114, 1993.
9. Finlay, C. A. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol. Cell. Biol., 13: 301-306, 1993.
10. Lin, J., Chen, J., Elenbaas, B., and Levine, A. J. Several hydrophobic amino acids in the p53 amino-termmal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 EIB 55- 54 6D protein. Genes Dev., 8: 1235-1246, 1994.
11. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. Mdm2 promotes the rapid degradation of p53. Nature (Lond.), 387: 296-299, 1997.
12. Haupt, Y., Barak, Y., and Oren, M. Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J., 15: 1596-1606, 1996.
13. Montes de Oca Luna, R., Wagner, D. S., and Lozano, G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature (Lond.), 378: 203-206, 1995.
14. Jones, S. N., Roe, A. E., Donehower, L. A., and Bradley, A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature (Lond.), 378: 206-208, 1995.
15. Hartwell, L. H., and Kastan, M. B. Cell cycle control and cancer. Science (Washington DC), 266: 1821-1828, 1994.
16. Pomerantz, J., Schreiber-Agus, N., Liegeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H. W., Cordon-Cardo, C., DePinho RA. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell, 92: 713-723 1998.
17. 1 cell-cycle arrest. Oncogene, 11: 2445-2449, 1995.
18. Lundgren, K., Montes de Oca Luna, R., McNeill, Y. B., Emerick, E. P., Spencer, B., Barfield, C. R., Lozano, G., Rosenberg, M. P., Finlay, C. A. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev., 11: 714-725, 1997.
19. Reinke, V., Bortner, D. M., Ameise, L. L., Lundgren, K., Rosenberg, M. P., Finlay, C. A., and Lozano, G. Overproduction of MDM2 in vivo disrupts S phase independent of E2F1. Cell Growth Differ., 10: 147-154, 1999.
20. Xiao, Z. X., Chen, J., Levine, A. J., Modjtahedl, N., Xing, J., Sellers, W. R., and Livingston, D. M. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature (Lond.), 575: 694-698, 1995.
21. Dyson, N. The regulation of E2F by pRB-family proteins. Genes Dev., 12: 2245-2262, 1998.
22. Martin, K., Trouche, D., Hagemeier, C., Srensen, T. S., LaThangue, N. B., and Kouzarides, T. Stipulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature (Lond.), 375: 691-694, 1995.
23. Singh, P., Wong, S. H., and Hong, W. Overexpression of E2F-1 in rat embryo fibroblasts leads to neoplastic transformation. EMBO J., 13: 3329-3338, 1994.
24. Johnson, D. G., Cress, W. D., Jakoi, L., and Nevins, J. R. Oncogenic capacity of the E2F1 gene. Proc. Natl. Acad. Sci. USA, 91: 12823-12827, 1994.
25. Xu, G., Livingston, D. M., and Krek, W. Multiple members of the E2F transcription factor family are the products of oncogenes. Proc. Natl. Acad. Sci. USA, 92: 1357-1361, 1995.
26. Helin, K. Regulation of cell proliferation by the E2F transcription factors. Curr. Opin. Genet. Dev., 8: 28-35, 1998.
27. Johnson, D. G., Schwarz, J. K., Cress, W. D., and Nevins, J. R. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature (Lond.), 365: 349-352, 1993.
28. Kowalik, T. F., DeGregori, J., Schwarz, J. K., and Nevins, J. R. E2F1 Overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J. Virol., 69: 2491-2500, 1995.
29. Pierce, A. M., Fisher, S. M., Conti, C. J., and Johnson, D. G. Deregulated expression of E2F1 induces hyperplasia and cooperates with ras in skin tumor development. Oncogene, 16: 1267-1276, 1998.
30. Holmberg, C., Helin, K., Sehested, M., and Karlstrom, O. E2F-1-induced p53-independent apoptosis in transgenic mice. Oncogene, 17: 143-155, 1998.
31. Yamasaki, L., Jacks, T., Bronson, R., Goillot, E., Harlow, E., and Dyson, N. J. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell, 85: 537-548, 1996.
32. Field, S. J., Tsai, F. Y., Kou, F., Zubiaga, A. M., Kaelin, W. G., Livingston, D. M., Orkin, S. H., and Greenberg, M. E. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell, 85: 549-561, 1996.
33. Pan, H., Yin, C., Dyson, N. J., Harlow, E., Yamasaki, L., and Van Dyke, T. Key roles for E2F1 in signaling p53-dependent apoptosis and in cell division within developing tumors. Mol. Cell, 2: 283-292, 1998.
34. Yamasaki, L., Bronson, R., Williams, B. O., Dyson, N. J., Harlow, E., and Jacks, T. Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/-) mice. Nat. Genet., 18: 360-364, 1998.
35. Wu, X. W., and Levine, A. J. p53, and E2F-1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci. USA, 91: 3602-3606, 1994.
36. Shan, B., and Lee, W. H. Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol. Cell. Biol., 14: 8166-8173, 1994.
37. Qin, X. Q., Livingston, D. M., Kaelin, W. G., Jr., and Adams, P. D. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc. Natl. Acad. Sci. USA, 91: 10918-10922, 1994.
38. Phillips, A. C., Bates, S., Ryan, K. M., Helin, K., and Vousden, K. H. Induction of DNA synthesis and apoptosis are separable functions of E2F-1. Genes Dev., 11: 1853-1863, 1997.
39. Hsieh, J. K., Fredersdorf, S., Kouzarides, T., Martin, K., and Lu, X. E2F1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction. Genes Dev., 11: 1840-1852 1997.
40. Nip, J., Strom, D. K., Fee, B. E., Zambetti, G., Cleveland, J., and Hiebert, S. W. E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis. Mol. Cell. Biol., 17: 1049-1056, 1997.
41. Meng, R. D., Shih, H., Prabhu, N. S., George, D. L., and el-Deiry, W. S. Bypass of abnormal MDM2 inhibition of p53-dependent growth suppression. Clin. Cancer Res., 4: 251-259, 1998.
42. Hunt, K. K., Deng, J., Liu, T. J., Wilson-Heiner, M., Swisher, S. G., Clayman, G. L., and Hung, M. C. Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53. Cancer Res., 57: 4722-4726, 1997.
43. Fueyo, J., Gomez-Manzano, C., Yung, W. K., Liu, T. J., Alemany, R., McDonnell, T. J., Shi, X., Rao, J. S., Levin, V. A., and Kyritsis, A. P. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat. Med., 4: 685-690, 1998.
44. Frank, D. K., Liu, T. J., Frederick, M. J., and Clayman, G. L. Combination E2F-1 and p53 gene transfer does not enhance growth inhibition in human squamous cell carcinoma of the head and neck. Clin. Cancer Res., 4: 2265-2272, 1998.
45. Gomez-Manzano, C., Fueyo, J., Alameda, F., Kyritsis, A. P., and Yung, W. K. Gene therapy for gliomas: p53 and E2F-1 proteins and the target of apoptosis. Int. J. Mol. Med., 3: 81-85, 1999.
46. Kowalik, T. F., DeGregori, J., Leone, G., Jakoi, L., and Nevins, J. R. E2F-1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2. Cell Growth Differ., 9: 113-118, 1998.
47. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D., and Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas [see comments]. Nature (Lond.), 358: 80-83, 1992.
48. Fakharzadeh, S. S., Trusko, S. P., and George, D. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J., 10: 1565-1569, 1991.
49. French, B. A., Mazur, W., Ali, N. M., Geske, R. S., Finnigan, J. P., and Rodgers, G. P. Percutaneous transluminal in vivo gene transfer by recombinant adenovirus in normal porcine coronary arteries, atherosclerotic arteries, and two models of coronary restenosis. Circulation, 90: 2402-2413, 1994.
50. Graham, F. L., and Prevec, L. Manipulation of adenovirus vectors. In: E. J. Murray (ed.), Gene Transfer and Expression Protocols, Methods in Molecular Biology, Vol. 7, pp. 109-128. Clifton, NJ: The Humana Press, Inc., 1991.
51. Adams, D. O., Edelson, P. H., and Korren, M. S. Methods for Studying Mononuclear Phagocytes. New York: Academic Press, 1981.
52. Lock, R. B., Galperina, O. V., Feldhoff, R. C., and Rhodes, L. J. Concentration-dependent differences in the mechanisms by which caffeine potentiates etoposide cytotoxicity in HeLa cells. Cancer Res., 54: 4933-4939, 1994.
53. He, J., Whitacre, C. M., Xue, L. Y., Berger, N. A., and Oleinick, N. L. Protease activation and cleavage of poly(ADP-ribose) polymerase: an integral part of apoptosis in response to photodynamic treatment. Cancer Res., 58: 940-946, 1998.
54. Gavriell, Y., Sherman, Y., and Ben-Sasson, S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol., 3: 493-501, 1992.
55. Hiebert, S. W., Packham, G., Strom, D. K., Haffner, R., Oren, M., and Zambetti, G. E2F-1:DP-1 induces p53 and overrides survival factors to trigger apoptosis. Mol. Cell. Biol., 15: 6864-6874, 1995.
56. Wood, D. E., and Newcomb, E. W. Caspase-dependent activation of calpain during drug-induced apoptosis. J. Biol. Chem., 274: 8309-8315, 1999.
57. Wood, D. E., Thomas, A., Devi, L. A., Berman Y., Beavis, R. C., Reed, J. C., and Newcomb, E. W. Bax cleavage is mediated by calpain during drug-induced apoptosis. Oncogene, 17: 1069-1078, 1998.
58. Erhardt, P., Tomaselli, K. J., and Cooper, G. M. Identification of the MDM2 oncoprotein as a substrate for CPP32-like apoptotic proteases. J. Biol. Chem., 272: 15049-15052,1997.
59. Chen, L., Marechal, V., Moreau, J., Levine, A. J., and Chen, J. Proteolytic cleavage of the mdm2 oncoprotein during apoptosis. J. Biol. Chem., 272: 22966-22973, 1997.
60. Pochampally, R., Fodera, B., Chen, L., Shao, W., Levine, E. A., Chen, J. A 60 kd MDM2 isoform is produced by caspase cleavage in non-apoptotic tumor cells. Oncogene, 17: 2629-2636 1998.